Medtronic launches Adaptive Deep Brain Stimulation System for Parkinson’s patients in India

Medtronic, a global leader in healthcare technology, has announced the launch of its Adaptive Deep Brain Stimulation (aDBS) system, an innovation over conventional DBS, in India to further improve quality of life of patients living with Parkinson’s disease.

The prevalence of Parkinson's disease (PD) in India is roughly 10% of the global burden, which is a considerable public health concern.

Treatment options like Deep Brain Stimulation exist which involve manual adjustment of stimulation levels throughout the day, usually managed by patients or caregivers.

Medtronic’s aDBS technology is designed to adapt real time to changes in a patient’s condition or medication needs—helping deliver more consistent symptom management. The aDBS system uses BrainSense™ technology, which has been approved by the US Food and Drug Administration (FDA).

Adaptive deep brain stimulation (aDBS) is designed to automatically adjust therapy based on changes in brain signals or patient activity. By responding in real time, it aims to provide more consistent symptom control, minimize side effects, and help extend the life of the implanted device’s battery.

With India expected to witness a significant rise in Parkinson’s disease cases—projected to become the second-highest globally within the next five years—the introduction of the aDBS system comes at a critical time. Although there is currently no cure for conditions such as Parkinson’s disease, deep brain stimulation (DBS) has been transforming the lives of patients with Parkinson’s and other neurological disorders for more than three decades. 

DBS uses a small, pacemaker-like device, placed under the skin of the chest, to send electronic signals to an area in the brain that controls movement.